In December 2016, Philip Morris International (PMI) had announced that it submitted a Modified Danger Tobacco Item (MRTP) application with the FDA’s Center for Tobacco Solutions, for its Heat Not Burn device, iQOS.
The FDA panel did not prove that the device lowered the danger of smoking connected ailments, nevertheless they did agree that working with iQOS alternatively of frequent cigarettes, would considerably decrease a person’s exposure to damaging chemical compounds.
In 2018, an FDA panel reviewed the iQOS application, and voted to reject more than a million pages of proof, dismissing PMI’s claim that their iQOS heated tobacco item is a safer option to tobacco.
Advertising restrictions set in location to shield minors
This vote nevertheless, was not the final act in figuring out the fate of the MRTP application for iQOS, as the FDA is not obliged to comply with the panel’s suggestions. Lastly final Might, the agency authorized the item, while enforcing sensible promoting restrictions, such as ones guaranteeing that the item will not be marketed to teenagers.
“The FDA is placing in location post-industry needs aimed at, amongst other issues, monitoring industry dynamics such as prospective youth uptake,” stated Mitch Zeller, director of the FDA’s Center for Tobacco Solutions.
Meanwhile, PMI stated that it chose Atlanta to test promoting and sales methods for iQOS, due to the area’s “several hundred thousand” adult smokers, adding that it will operate to reduce teen exposure to the item.
Study Additional: WABE